Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

NCT00975143 is registered in ClinicalTrials.gov with Cipher Pharmaceuticals Inc. as lead sponsor.

NCT NCT00975143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00975143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
Lead sponsor
Cipher Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
May 31, 2011
Enrollment
925 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

severe nodular acne